Cointime

Cellerant Therapeutics

company

About

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies.

  • 101 - 250

Highlights

Total Funding Amount
$28.09M
Funding Rounds
3
Investors
3

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$2.09M
Industries
Biotechnology,Clinical Trials,Therapeutics
Founded date
Jan 1, 2003
Number Of Employee
101 - 250
Operating Status
Active

Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s Romyelocel-L is a universal cell therapy that does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia.

It was founded in 2003 and headquartered in San Carlos, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$28.09M
Cellerant Therapeutics has raised a total of $28.09M in funding over 2 rounds. Their latest funding was raised on Sep 28, 2012 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 28, 2012 Series Unknown $2.09M 2 — — Detail
May 11, 2005 Series B $16M 2 Novel Bioventures — Detail
May 29, 2003 Series A $10M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Cellerant Therapeutics is funded by 3 investors. Novel Bioventures and Camelot Collectables are the most recent investors.
Investor Name Lead Investor Funding Round
Novel Bioventures Yes Series B
Camelot Collectables — Series Unknown
Allen & Company — Series Unknown
Cointime
เนื้อหา
บริษัท